Indications
Nerlynx is indicated for the extended adjuvant treatment of adult patients with early stage hormone receptor positive HER2-overexpressed/amplified breast cancer and who are less than one year from the completion of prior adjuvant trastuzumab based therapy.
Composition
- Active substance
- neratinib
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Nerlynx
- Active substance
- neratinib
- ATC code
- L01EH02
- Therapeutic area
- Breast Neoplasms
- Marketing authorisation holder
- Pierre Fabre Medicament
- Status